Related Experiment Video
Updated: Jun 12, 2026
08:28
Assessment of the Effects of Endocrine Disrupting Compounds on the Development of Vertebrate Neural Network Function Using Multi-electrode Arrays
Published on: April 26, 2018
Biomonitoring Equivalents for bisphenol A (BPA)
Kannan Krishnan1, Michelle Gagné, Andy Nong
1Département de Santé Environnementale et Santé au Travail, Université de Montréal, Montréal, QC, Canada.
Regulatory Toxicology and Pharmacology : RTP
|June 15, 2010
Summary
Biomonitoring Equivalents (BEs) provide health context for chemical levels in the body. New BE values for Bisphenol A (BPA) help interpret human biomonitoring data for risk assessment.
Area of Science:
- Environmental Health
- Toxicology
- Risk Assessment
Background:
- Growing biomonitoring data lacks interpretation tools for health risk.
- Biomonitoring Equivalents (BEs) bridge exposure guidelines and measured body burdens.
- Bisphenol A (BPA) is a chemical of interest with existing exposure guidance values.
Purpose of the Study:
- To derive Biomonitoring Equivalents (BEs) for Bisphenol A (BPA).
- To establish reference values for interpreting BPA concentrations in human urine.
- To facilitate the health risk assessment of BPA exposure using biomonitoring data.
Main Methods:
- Reviewed health-based exposure guidance values for BPA from Health Canada, US EPA, and EFSA.
- Integrated pharmacokinetic data, specifically human urinary excretion of BPA.
- Calculated BE values based on established exposure limits and excretion data.
Main Results:
- Derived BE value for Health Canada's pTDI (25 microg/kg-d) is 1 mg/L (1.3 mg/g creatinine).
- Derived BE value for US EPA RfD and EFSA TDI (50 microg/kg-d) is 2 mg/L (2.6 mg/g creatinine).
- These BE values represent 24-h average urinary BPA concentrations at steady-state exposure.
Conclusions:
- Derived BE values serve as screening tools for population biomonitoring data of BPA.
- BEs aid in evaluating BPA exposure in a health risk context.
- These values can help prioritize further risk assessment efforts for BPA.
Related Concept Videos
01:27Bioplastics
Bioplastics derived from microbial processes present a sustainable alternative to conventional petroleum-based plastics. Among these, polyhydroxyalkanoates (PHAs), particularly polyhydroxybutyrates (PHBs), have emerged as prominent candidates due to their biodegradability and biocompatibility. These polymers are synthesized by a variety of bacteria, such as Cupriavidus necator and Pseudomonas putida, which naturally accumulate PHAs as intracellular carbon and energy reserves, especially under...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...